Aldeyra Therapeutics Files Q1 2025 10-Q
Ticker: ALDX · Form: 10-Q · Filed: May 14, 2025 · CIK: 1341235
| Field | Detail |
|---|---|
| Company | Aldeyra Therapeutics, INC. (ALDX) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, R&D
TL;DR
Aldeyra's Q1 2025 10-Q is in: R&D expenses and investment holdings detailed.
AI Summary
Aldeyra Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported financial data related to its common stock and investments in U.S. Government Agencies Debt Securities and Money Market Funds. Research and Development expenses for the first quarter of 2025 were also detailed.
Why It Matters
This filing provides insight into Aldeyra Therapeutics' financial position and operational expenses for the first quarter of 2025, which can influence investor decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Aldeyra Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-01-01 — Start of Q1 2025 (Marks the beginning of the reporting period for financial activities.)
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 (address) — Company's business and mailing address
- 781-761-4904 (phone_number) — Company's business phone number
FAQ
What were Aldeyra Therapeutics' Research and Development expenses for the first quarter of 2025?
The filing indicates Research and Development expenses for the period January 1, 2025 to March 31, 2025.
What types of investments does Aldeyra Therapeutics hold as of March 31, 2025?
As of March 31, 2025, Aldeyra Therapeutics held U.S. Government Agencies Debt Securities and Money Market Funds.
What is the company's primary industry classification?
Aldeyra Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834].
When was the company formerly known as Neuron Systems Inc?
The company was formerly known as Neuron Systems Inc, with a date of name change in 20051012.
What is the fiscal year end for Aldeyra Therapeutics?
The fiscal year end for Aldeyra Therapeutics is December 31 (1231).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Aldeyra Therapeutics, Inc. (ALDX).